Compare Pfizer Inc (PFE) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Twilio Inc — how do they compare? Pfizer Inc trades at $27.74 (market cap $159.59B), while Twilio Inc trades at $276.52 (market cap $41.93B). The key difference: Pfizer Inc is far larger — about 3.8× Twilio Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Twilio Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Twilio Inc for 56 Days on average.
| PFE | TWLO | |
|---|---|---|
Market Cap | $159.59B | $41.93B |
Volume | 30,937,010 | 3,480,421 |
Sector | Health | Technology |
52-Week High | $29.02 | $301.27 |
52-Week Low | $23.67 | $106.23 |
Typical Hold Time | 158 Days | 56 Days |
Enterprise Value | $211.09B | $40.34B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Twilio (TWLO) trades at $275.77, down 1.65% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue growth accelerated to $5.07 billion in 2025, and net income turned positive at $33.83 million, marking a significant improvement from prior losses. Recent inclusion in the S&P 500 index highlights its market recognition and stability.
The outlook remains positive with strong analyst support (76.92% buy ratings) and a consensus price target of $254.65, though current price exceeds this. Key risks include high valuation multiples (P/E 37.71, EV/EBITDA 80.78) and competitive pressures in the customer engagement space. Upside potential hinges on sustained earnings beats and Voice AI adoption, but investors should monitor margin trends and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
